Article ID Journal Published Year Pages File Type
5702616 Urologic Oncology: Seminars and Original Investigations 2017 7 Pages PDF
Abstract
The approved single-agent doses of mitoxantrone and cabazitaxel were safely combined. The combination led to durable tumor responses in most patients. Further study of the combination is warranted.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Oncology
Preview
A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study
Authors
, , , , , , , , , , , , , , ,